Tyra Biosciences Reports Increased Loss Amid R&D Investments

Tyra Bioscience, Inc ( (TYRA) ) has released its Q3 earnings. Here is a breakdown of the information Tyra Bioscience, Inc presented to its investors.

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology, using its SNÅP platform for rapid drug design. In its latest earnings report for the quarter ending September 30, 2025, the company highlighted a significant net loss of $29.9 million, compared to a $24 million loss in the same period last year, driven by increased research and development expenses. Key financial metrics indicate a decrease in cash and cash equivalents to $61.9 million from $91.9 million at the end of 2024, alongside a reduction in marketable securities. The company reported total operating expenses of $32.9 million, primarily due to research and development costs, which rose to $25.5 million. Despite the losses, Tyra Biosciences continues to invest heavily in its pipeline, with significant expenditures on its lead programs, including Dabogratinib and TYRA-430. Looking ahead, the management remains focused on advancing its drug candidates through clinical trials, with an emphasis on leveraging its SNÅP platform to address resistance in existing therapies.